



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.
10 057,487	01 25 2002	Lisa A. Racie	08702.0073-00000	3565
25291	7590	06 03 2003		
WYETH PATENT LAW GROUP FIVE GIRALDA FARMS MADISON, NJ 07940			EXAMINER	
			SLOBODYANSKY, ELIZABETH	
			ART UNIT	PAPER NUMBER
			1652	
			DATE MAILED: 06 03 2003	1

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/057,487	RACIE ET AL.
	Examiner Elizabeth Slobodyansky	Art Unit 1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 2 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 14 March 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-27 is/are pending in the application.

4a) Of the above claim(s) 1-13, 15 and 17-27 is/are withdrawn from consideration.

5) Claim(s) 14 and 16 is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>6</u> .	6) <input type="checkbox"/> Other: _____ .

Art Unit: 1652

DETAILED ACTION

The amendment filed March 14, 2003 (Paper No.9) amending claims 14 and 16 has been entered.

Claims 1-27 are pending.

Election/Restriction

Applicant's election with traverse of Group V, claims 14 and 16, in Paper No.9 is acknowledged. The traversal is on the ground(s) that "The search and examination of this application do not constitute a serious burden because of the close relationship among the sequences" (Remarks, page 1). This is not found persuasive because it is unclear which specific Groups are discussed. As for the entire application, the inventions of separate Groups are independent and distinct for the reasons given previously in the Office action mailed February 19, 2003. *"For purposes of the initial requirement, a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search as defined in MPEP 808.02."* (see MPEP 803).

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-13, 15 and 17-27 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected Groups I-IV and VI-XII, there being

Art Unit: 1652

no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No.9.

Priority

SEQ ID NO:8 is not disclosed in the parent application 09/978,979. Therefore, for the purposes of the prior art, the filing date of the instant application is its actual filing date of January 25, 2002.

Specification

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825. 37 CFR 1.821(d) requires the use of assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences. Figure 1 represents the nucleotide sequence without the sequencer identifier being used either in the drawing or in the Brief Description of the Drawings. Furthermore, for example, on pages 16, 19-22, 24, 25, the sequences are recited without references to the sequence identifiers.

Appropriate correction is required.

Art Unit: 1652

The following is an examiner's statement of reasons for allowance:

While Zheng et al. (November 2001) teach ADAMTS13 having the amino acid sequence of 1427 residues that differs from SEQ ID NO:8 by two substitutions W7R and A900Y, thorough searches of the prior art revealed no previous teaching or suggestion of an aggrecanase or any other protein having the amino acid sequence of SEQ ID NO:8.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

This application is in condition for allowance except for the following formal matters: 1. non-elected claims should be canceled. 2. the application must comply with the requirements of 37 CFR 1.821 through 1.825.

Prosecution on the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

A shortened statutory period for reply to this action is set to expire **TWO MONTHS** from the mailing date of this letter.

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky whose telephone number is (703) 306-3222. The examiner can normally be reached Monday through Friday from 9:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy, can be reached at (703) 308-3804. The FAX phone number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Center receptionist whose telephone number is (703) 308-0196.

E. Slobodyansky
Elizabeth Slobodyansky, PhD
Primary Examiner

May 29, 2003